TP10 data

TCEL (Needham, Mass.) presented Phase I data with five doses in 24 patients with acute lung injury who were at risk for ARDS, showing no adverse effects or lab test abnormalities.

As reported at the meeting of the American College of Chest Physicians in New York, escalating doses of 0.1 to 10 mg/kg, given as an infusion over 30 minutes, also reduced activation of the complement cascade as doses were increased. The half-life was 30 hours. ...